MetLife Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $28.8M | Sell |
58,072
-12,732
| -18% | -$5.64M | 0.13% | 105 |
|
|
2026
Q1 | $31.6M | Sell |
70,804
-2,477
| -3% | -$1.16M | 0.16% | 91 |
|
|
2025
Q4 | $33.2M | Sell |
73,281
-2,526
| -3% | -$1.09M | 0.16% | 90 |
|
|
2025
Q3 | $29.7M | Sell |
75,807
-1,341
| -2% | -$560K | 0.14% | 98 |
|
|
2025
Q2 | $34.3M | Buy |
77,148
+4,787
| +7% | +$2.21M | 0.2% | 77 |
|
|
2025
Q1 | $35.1M | Sell |
72,361
-1,523
| -2% | -$710K | 0.19% | 79 |
|
|
2024
Q4 | $29.8M | Buy |
73,884
+873
| +1% | +$405K | 0.16% | 92 |
|
|
2024
Q3 | $34M | Sell |
73,011
-1,828
| -2% | -$878K | 0.19% | 77 |
|
|
2024
Q2 | $35.1M | Buy |
74,839
+4,749
| +7% | +$2.06M | 0.21% | 76 |
|
|
2024
Q1 | $29.3M | Sell |
70,090
-2,181
| -3% | -$922K | 0.2% | 80 |
|
|
2023
Q4 | $29.4M | Sell |
72,271
-1,383
| -2% | -$511K | 0.21% | 75 |
|
|
2023
Q3 | $25.6M | Sell |
73,654
-1,544
| -2% | -$540K | 0.2% | 85 |
|
|
2023
Q2 | $26.5M | Sell |
75,198
-762
| -1% | -$257K | 0.19% | 90 |
|
|
2023
Q1 | $23.9M | Sell |
75,960
-676
| -0.9% | -$203K | 0.17% | 98 |
|
|
2022
Q4 | $22.1M | Sell |
76,636
-1,447
| -2% | -$441K | 0.17% | 103 |
|
|
2022
Q3 | $22.6M | Sell |
78,083
-711
| -0.9% | -$205K | 0.19% | 85 |
|
|
2022
Q2 | $22.2M | Buy |
78,794
+4,969
| +7% | +$1.33M | 0.17% | 97 |
|
|
2022
Q1 | $19.3M | Buy |
73,825
+17,650
| +31% | +$4.19M | 0.12% | 128 |
|
|
2021
Q4 | $12.3M | Sell |
56,175
-2,419
| -4% | -$470K | 0.1% | 159 |
|
|
2021
Q3 | $10.6M | Sell |
58,594
-1,422
| -2% | -$278K | 0.1% | 167 |
|
|
2021
Q2 | $12.1M | Sell |
60,016
-1,933
| -3% | -$404K | 0.11% | 157 |
|
|
2021
Q1 | $13.3M | Sell |
61,949
-1,202
| -2% | -$264K | 0.12% | 141 |
|
|
2020
Q4 | $14.9M | Sell |
63,151
-2,889
| -4% | -$663K | 0.14% | 127 |
|
|
2020
Q3 | $18M | Sell |
66,040
-1,771
| -3% | -$489K | 0.2% | 87 |
|
|
2020
Q2 | $19.7M | Buy |
67,811
+1,527
| +2% | +$414K | 0.22% | 82 |
|
|
2020
Q1 | $15.8M | Sell |
66,284
-2,028
| -3% | -$465K | 0.21% | 86 |
|
|
2019
Q4 | $15M | Sell |
68,312
-1,637
| -2% | -$331K | 0.16% | 120 |
|
|
2019
Q3 | $11.9M | Sell |
69,949
-648
| -0.9% | -$115K | 0.13% | 151 |
|
|
2019
Q2 | $12.9M | Sell |
70,597
-2,076
| -3% | -$363K | 0.14% | 134 |
|
|
2019
Q1 | $13.4M | Sell |
72,673
-411
| -0.6% | -$75.9K | 0.15% | 127 |
|
|
2018
Q4 | $12.1M | Sell |
73,084
-1,259
| -2% | -$218K | 0.15% | 131 |
|
|
2018
Q3 | $14.3M | Sell |
74,343
-673
| -0.9% | -$120K | 0.15% | 124 |
|
|
2018
Q2 | $12.8M | Sell |
75,016
-1,390
| -2% | -$215K | 0.15% | 125 |
|
|
2018
Q1 | $12.5M | Sell |
76,406
-1,844
| -2% | -$301K | 0.15% | 129 |
|
|
2017
Q4 | $11.7M | Buy |
+78,250
| New | +$11.6M | 0.13% | 140 |
|
Other funds holding VRTX
MetLife Investment Management's VRTX Position: Q2 2026 in Review
MetLife Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 18% in Q2 2026, selling an estimated $5.64M and leaving 58,072 shares worth $28.8M. The position accounts for 0.13% of the portfolio, ranked #105.
MetLife Investment Management first reported a position in VRTX in Q4 2017 and has held it in 35 quarters since. The position peaked at $35.1M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- MetLife Investment Management held 58,072 shares of Vertex Pharmaceuticals worth $28.8M as of Q2 2026.
- MetLife Investment Management sold 12,732 Vertex Pharmaceuticals shares in Q2 2026, an estimated $5.64M.
- Vertex Pharmaceuticals made up 0.13% of MetLife Investment Management's portfolio in Q2 2026, its #105 holding.
- MetLife Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Vertex Pharmaceuticals position peaked at $35.1M in Q1 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.